Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2007

View Archived Issues

Novel therapeutic agents for thrombotic and other blood coagulation disorders reported in patents

Heat shock protein 70 gene therapy safe, effective in phase I cancer study

Favorable endometrial profile seen with bazedoxifene in postmenopausal women

Progress on gene therapies reported

THCV begins phase I for obesity and metabolic disorders

Eurand and GSK reach milestone in orally disintegrating tablet collaboration

Sunesis earns milestone on progress of novel LFA-1 inhibitor candidate

MAGE-A3 cancer immunotherapeutic begins phase III study in NSCLC

Novel analgesic agents imparted in recent patent literature

New treatment options for neurological disorders reported in recent patent literature

Phase III enrollment stopped for SECTA therapy on DMC advice

Further development of XTL-2125 suspended

Interim RECORD data support Avandia safety; FDA requests more prominent product labeling

M-0002 begins phase IIa study in ascites

SLx-4090 studied in new phase IIa for dyslipidemia

Modulation of purinergic P2X and P2X2/3 receptors, a new strategy for treating urinary incontinence

Indigo inlicenses drug for treatment of arteriosclerosis obliterans

Amgen to acquire Alantos

CYT-107 to begin phase I/IIa trials in hepatitis C and oncology

Oral laquinimod to begin phase III program in relapsing MS

PF-562271 associated with activity and manageable toxicity in ongoing phase I trial

Tapestry's third-generation taxane TPI-287 advances through the pipeline

Targeted chemotherapeutic EC-145 advances to phase II clinical trials

Ongoing phase I clinical trials evaluating different dose schedules of E-7974

Antisense p53 production inhibitor improves efficacy and tolerability of cytarabine/idarubicin

Actemra significantly improves signs and symptoms of rheumatoid arthritis

AN-2728 shows comparable efficacy to betamethasone and tacrolimus in psoriasis

Japanese priority review for Taxotere in hormone refractory prostate cancer

E.U. approval for Humira for severe Crohn's disease

Remicade approved in E.U. for pediatric Crohn's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...